Free Trial

Incannex Healthcare (IXHL) FDA Events

Incannex Healthcare logo
$0.22 0.00 (-0.86%)
As of 01:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
FDA Events for Incannex Healthcare (IXHL)

This section highlights FDA-related milestones and regulatory updates for drugs developed by Incannex Healthcare (IXHL). Over the past two years, Incannex Healthcare has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as CannQuit-N, CannQuit-O, IHL-42X, and PSX-001. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

Incannex Healthcare's Drugs in FDA Review

CannQuit-N - FDA Regulatory Timeline and Events

CannQuit-N is a drug developed by Incannex Healthcare for the following indication: for tobacco smoking cessation and control of relapse. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

CannQuit-O - FDA Regulatory Timeline and Events

CannQuit-O is a drug developed by Incannex Healthcare for the following indication: for the treatment of opioid use disorder (OUD). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

IHL-42X - FDA Regulatory Timeline and Events

IHL-42X is a drug developed by Incannex Healthcare for the following indication: Obstructive Sleep Apnoea (OSA). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

PSX-001 - FDA Regulatory Timeline and Events

PSX-001 is a drug developed by Incannex Healthcare for the following indication: In Patients with Generalised Anxiety Disorder to Proceed. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Incannex Healthcare FDA Events - Frequently Asked Questions

However, the company does has had drugs under review or in active clinical development.

In the past two years, Incannex Healthcare (IXHL) has reported FDA regulatory activity for the following drugs: IHL-42X, PSX-001, CannQuit-O and CannQuit-N.

The most recent FDA-related event for Incannex Healthcare occurred on June 18, 2025, involving IHL-42X. The update was categorized as "Provided Update," with the company reporting: "Incannex Healthcare Inc. is pleased to announce that it has achieved database lock for the RePOSA Phase 2 clinical trial of IHL-42X, its lead drug candidate for obstructive sleep apnoea (OSA), on schedule as of 16 June 2025."

Current therapies from Incannex Healthcare in review with the FDA target conditions such as:

  • Obstructive Sleep Apnoea (OSA) - IHL-42X
  • In Patients with Generalised Anxiety Disorder to Proceed - PSX-001
  • for the treatment of opioid use disorder (OUD). - CannQuit-O
  • for tobacco smoking cessation and control of relapse. - CannQuit-N

More FDA Event Resources from MarketBeat

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

This page (NASDAQ:IXHL) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners